Search Results - "Clark, AS"

Anabolic androgenic steroids and forebrain GABAergic transmission by Henderson, L.P., Penatti, C.A.A., Jones, B.L., Yang, P., Clark, A.S.

“…Anabolic androgenic steroids are synthetic derivatives of testosterone designed for therapeutic purposes, but now taken predominantly as drugs of abuse. The…”
Get full text

Integrated spatial multiplexing of heralded single-photon sources by Collins, M.J., Xiong, C., Rey, I.H., Vo, T.D., He, J., Shahnia, S., Reardon, C., Krauss, T.F., Steel, M.J., Clark, A.S., Eggleton, B.J.

“…The non-deterministic nature of photon sources is a key limitation for single-photon quantum processors. Spatial multiplexing overcomes this by enhancing the…”
Get full text

Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation by BROGNARD, John, CLARK, Amy S, YUCHENG NI, DENNIS, Phillip A

“…To evaluate the role of Akt/PKB in non-small cell lung cancer (NSCLC) survival, we analyzed NSCLC cell lines that differed in tumor histology as well as p53,…”
Get full text

Constitutive and Inducible Akt Activity Promotes Resistance to Chemotherapy, Trastuzumab, or Tamoxifen in Breast Cancer Cells by Clark, Amy S, West, Kip, Streicher, Samantha, Dennis, Phillip A

“…To evaluate the role of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in breast cancer cell survival and therapeutic resistance, we analyzed a panel of…”
Get full text

Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor by Bardia, A, Hurvitz, S, Yardley, DA, Zelnak, A, DeMichele, A, Clark, AS, Warsi, G, Small, T, Tucci, C, Moulder, S

“…Abstract Background: There is extensive crosstalk between the cyclin D–CDK4/6–inhibitor of CDK4–retinoblastoma and phosphatidylinositol 3-kinase…”
Get full text

Behavioral and physiological responses to anabolic-androgenic steroids by Clark, Ann S, Henderson, Leslie P

“…Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone originally designed for therapeutic uses to provide enhanced anabolic potency with…”
Get full text

Partial validation of a TaqMan real-time quantitative PCR assay for the detection of Panulirus argus virus 1 by Clark, Abigail S, Behringer, Donald C, Moss Small, Jessica, Waltzek, Thomas B

“…The Caribbean spiny lobster Panulirus argus supports important fisheries throughout the greater Caribbean and is also the only known host for the pathogenic…”
Get full text

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells by West, Kip A, Brognard, John, Clark, Amy S, Linnoila, Ilona R, Yang, Xiaowei, Swain, Sandra M, Harris, Curtis, Belinsky, Steven, Dennis, Phillip A

“…Tobacco-related diseases such as lung cancer cause over 4.2 million deaths annually, with approximately 400,000 deaths per year occurring in the US. Genotoxic…”
Get full text

Abstract P6-01-02: Flourine-18-fluorodeoxyglucose positron emission tomography for the evaluation of response to therapy in bone-dominant metastatic breast cancer: Examination in patients enrolled on UPCC 17113 by Lynch, MC, Mankoff, D, Bradbury, AR, Domchek, S, Glick, JH, Matro, J, DeMichele, A, Clark, AS

“…Abstract Background: Response of bone-only (BO) and bone-dominant (BD) metastatic breast cancer (mBC) to therapy is difficult to assess by conventional…”
Get full text

Abstract P2-08-03: Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer by DeMichele, AM, Clark, AS, Holmes, R, Volpe, M, Medrano, C, Troxel, A, Fox, K, Domchek, S, Matro, J, Bradbury, A, Shih, N, Feldman, M, Hexner, E, Bromberg, J

“…Abstract Background: In vitro mechanisms link IL-6 to poor outcome in breast cancer via inflammatory pathways, activated JAK/STAT tumor signaling and…”
Get full text

Abstract P4-22-14: Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer by Clark, AS, Wang, X, Troxel, A, Burrell, J, Feldman, M, Lal, P, Zhang, P, Rosen, M, Gallagher, M, Ndicu, J, Nivar, I, Matro, J, Domchek, SM, Fox, KR, O'Dwyer, P, DeMichele, A

“…Abstract Background: The Cyclin D/CDK4/6/Rb axis is dysregulated in breast cancer (BC). Palbociclib (P) is an oral agent that specifically inhibits CDK 4/6 and…”
Get full text

Hippocampal spatial representations require vestibular input by Stackman, Robert W., Clark, Ann S., Taube, Jeffrey S.

“…The hippocampal formation is essential for forming declarative representations of the relationships among multiple stimuli. The rodent hippocampal formation,…”
Get full text

Abstract OT2-07-09: Detection and targeting of minimal residual disease in breast cancer to reduce recurrence: The PENN-SURMOUNT and CLEVER trials by Bayne, LJ, Nivar, I, Goodspeed, B, Wileyto, P, Savage, J, Shih, NNC, Feldman, MD, Edwards, J, Clark, AS, Fox, KR, Matro, JM, Domchek, SM, Bradbury, AR, Shah, PD, Chislock, EM, Belka, GK, Wang, J, Amaravadi, R, Chodosh, LA, DeMichele, AM

“…Abstract Background: Recurrent breast cancers arise from minimal residual disease (MRD): the pool of disseminated and circulating tumor cells (DTCs and CTCs)…”
Get full text

Abstract PD4-07: PET imaging of PARP-1 expression in breast cancer by McDonald, ES, Carlin, S, Maxwell, KN, Nayak, A, Doot, RK, Pantel, AR, Farwell, MD, Pryma, DA, Clark, AS, Shah, P, DeMichele, AM, Ziober, A, Schubert, EK, Palmer, K, Lee, HS, Matro, J, de la Cruz, L, Tchou, J, Anderson, DN, Feldman, MD, Sheffer, RE, Knollman, H, Schnall, MD, Makvandi, M, Domchek, S, Hubbard, RA, Mach, RH, Mankoff, DA

“…Abstract 18F-FluorThanatrace ([18F]-FTT) is a novel radiotracer shown to quantify Poly [ADP-ribose] polymerase 1 (PARP-1) expression in vitro and in vivo…”
Get full text

Abstract P4-13-04: Upregulation of cell cycle pathway genes without loss of RB1 contributes to acquired resistance to single-agent treatment with palbociclib in breast cancer by DeMichele, A, Shih, NNC, Koehler, M, Huang Bartlett, C, Jiang, Y, Harwick, J, Huang, D, Zheng, X, Clark, AS, Colameco, C, Feldman, MD, Gallagher, M, Goodman, N, O'Dwyer, P, Rejto, P

“…Abstract Background: The oral cdk4/6 inhibitor, Palbociclib (Palbo), has been shown to prolong progression-free survival when combined with anti-estrogen…”
Get full text

Abstract P6-13-08: Palbociclib and paclitaxel on an alternating schedule for advanced breast cancer: Results of a phase Ib trial by Clark, AS, O'Dwyer, P, Troxel, A, Lal, P, Feldman, M, Gallagher, M, Driscoll, A, Colameco, C, Lewis, D, Rosen, M, Matro, J, Bradbury, A, Domchek, S, Fox, K, DeMichele, A

“…Abstract Background: Palbociclib (P) is an oral CDK 4/6 inhibitor (CDKi) that was recently FDA approved in combination with endocrine therapy for metastatic…”
Get full text

Abstract P3-06-10: Pretreatment Vitamin D Levels and Response to Neoadjuvant Chemotherapy in the I-SPY 1 TRIAL by Clark, AS, Chen, J, Kapoor, S, Esserman, LJ, DeMichele, A

“…Abstract Background: Vitamin D has been shown, in vitro, to promote differentiation and apoptosis while suppressing proliferation of breast cancer cells…”
Get full text

Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL by Silverstein, J, Suleiman, L, Yau, C, Price, ER, Singhrao, R, Yee, D, DeMichele, A, Isaacs, C, Albain, KS, Chien, AJ, Forero-Torres, A, Wallace, AM, Pusztai, L, Ellis, ED, Elias, AD, Lang, JE, Lu, J, Han, HS, Clark, AS, Korde, L, Nanda, R, Northfelt, DW, Khan, QJ, Viscusi, RK, Euhus, DM, Edmiston, KK, Chui, SY, Kemmer, K, Wood, WC, Park, JW, Liu, MC, Olopade, O, Leyland-Jones, B, Tripathy, D, Moulder, SL, Rugo, HS, Schwab, R, Lo, S, Helsten, T, Beckwith, H, Berry, DA, Asare, SM, Esserman, LJ, Boughey, JC, Mukhtar, RA

“…Abstract Background: In women with breast cancer receiving neoadjuvant chemotherapy, residual cancer burden (RCB) predicts distant recurrence and survival. In…”
Get full text

Artificial vaginocervical stimulation induces a conditioned place preference in female rats by Meerts, Sarah H., Clark, Ann S.

“…Female rats express a conditioned place preference (CPP) for a context paired with mating. During a mating encounter, the female rat is exposed to several…”
Get full text

Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden by Hylton, NM, Symmans, WF, Yau, C, Li, W, Hatzis, C, Isaacs, C, Albain, KS, Chen, Y-Y, Krings, G, Wei, S, Harada, S, Datnow, B, Fadare, O, Klein, M, Pambuccian, S, Chen, B, Adamson, K, Sams, S, Mhawech-Fauceglia, P, Magliocco, A, Feldman, M, Rendi, M, Sattar, H, Zeck, J, Ocal, I, Tawfik, O, Grasso LeBeau, L, Sahoo, S, Vinh, T, Yang, S, Adams, A, Chien, AJ, Ferero-Torres, A, Stringer-Reasor, E, Wallace, A, Boughey, JC, Ellis, ED, Elias, AD, Lang, JE, Lu, J, Han, HS, Clark, AS, Korde, L, Nanda, R, Northfelt, DW, Khan, QJ, Viscusi, RK, Euhus, DM, Edmiston, KK, Chui, SY, Kemmer, K, Wood, WC, Park, JW, Liu, MC, Olopade, O, Tripathy, D, Moulder, SL, Rugo, HS, Schwab, R, Lo, S, Helsten, T, Beckwith, H, Haugen, PK, van't Veer, LJ, Perlmutter, J, Melisko, ME, Wilson, A, Peterson, G, Asare, AL, Buxton, MB, Paoloni, M, Clennell, JL, Hirst, GL, Singhrao, R, Steeg, K, Matthews, JB, Sanil, A, Berry, SM, Abe, H, Wolverton, D, Crane, EP, Ward, KA, Nelson, M, Niell, BL, Oh, K, Brandt, KR, Bang, DH, Ojeda-Fournier, H, Eghtedari, M, Sheth, PA, Bernreuter, WK, Umphrey, H, Rosen, MA, Dogan, B, Yang, W, Joe, B, Yee, D, Pusztai, L, DeMichele, A, Asare, SM

“…Abstract Background: Patients achieving a pathologic complete response (pCR) following neoadjuvant therapy have significantly improved event-free survival…”
Get full text